Key result
A transgenic mouse model of LGMD2i (P448L mutation) exhibited 37% lower maximal activated tension in skeletal fibers and 18% lower in cardiac strips compared to controls.
Why the study?
Limb-girdle muscular dystrophy 2i compromises myofiber integrity and reduces power output in limb and cardiac muscles, but downstream effects on Ca2+-activated force generation and cross-bridge kinetics remained uncharacterized.
Does the P448L mutation alter Ca2+-activated force generation and cross-bridge kinetics in skeletal and cardiac muscle fibers in a mouse model of LGMD2i?
Does the P448L mutation alter Ca2+-activated force generation and cross-bridge kinetics in skeletal and cardiac muscle fibers in a mouse model of LGMD2i?
Decreased force production in LGMD2i may be partly due to altered cross-bridge kinetics, suggesting disease pathology involves downstream effects on cross-bridge behavior beyond sarcolemma properties.
Altered cross-bridge kinetics may contribute to LGMD2i weakness; animal findings leave open human cardiac relevance and require clinical validation.
Limb-girdle muscular dystrophy 2i (LGMD2i) is a dystroglycanopathy that compromises myofiber integrity and primarily reduces power output in limb muscles but can influence cardiac muscle as well. Previous studies of LGMD2i made use of a transgenic mouse model in which a proline-to-leucine (P448L) mutation in fukutin-related protein severely reduces glycosylation of α-dystroglycan. Muscle function is compromised in P448L mice in a manner similar to human patients with LGMD2i. In situ studies reported lower maximal twitch force and depressed force-velocity curves in medial gastrocnemius (MG) muscles from male P448L mice. Here, we measured Ca 2+ -activated force generation and cross-bridge kinetics in both demembranated MG fibers and papillary muscle strips from P448L mice. Maximal activated tension was 37% lower in MG fibers and 18% lower in papillary strips from P448L mice than controls. We also found slightly faster rates of cross-bridge recruitment and detachment in MG fibers from P448L than control mice. These increases in skeletal cross-bridge cycling could reduce the unitary force output from individual cross bridges by lowering the ratio of time spent in a force-bearing state to total cycle time. This suggests that the decreased force production in LGMD2i may be due (at least in part) to altered cross-bridge kinetics. This finding is notable, as the majority of studies germane to muscular dystrophies have focused on sarcolemma or whole muscle properties, whereas our findings suggest that the disease pathology is also influenced by potential downstream effects on cross-bridge behavior.
No takes yet. Share an insight, caveat, or question.
Fenwick et al. (2019) studied Limb-girdle muscular dystrophy 2i (LGMD2i). P448L mutation (transgenic mouse model) vs. Control mice was evaluated on Ca2+-activated force generation (maximal activated tension) and cross-bridge kinetics. A transgenic mouse model of LGMD2i (P448L mutation) exhibited 37% lower maximal activated tension in skeletal fibers and 18% lower in cardiac strips compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: